# New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

> **NCT01360021** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 214 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Symbicort
- **DRUG:** Symbicort
- **DRUG:** Budesonide

## Key facts

- **NCT ID:** NCT01360021
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2014-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01360021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01360021, "New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01360021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*